Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease

Radzikowski, Andrzej; Banaszkiewicz, Aleksandra; Łazowska-Przeorek, Izabella; Grzybowska-Chłebowczyk, Urszula; Woś, Halina; Pytrus, Tomasz; Iwańczak, Barbara; Kowalska-Duplaga, Kinga; Fyderek, Krzysztof; Gawrońska, Agnieszka; Karolewska-Bochenek, Katarzyna; Kotowska, Maria; Albrecht, Piotr

doi:10.1002/ibd.21465

Cited by 41 publications

(38 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Their results were consistent with existing reports of HAV seroconversion in healthy patients 2 and in patients with chronic liver disease. 3,4 Of note, none of the patients in the study were on a biologic medication, such as infliximab.…”

Section: To the Editorsupporting

confidence: 91%

See 1 more Smart Citation

Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab

Moses

Alkhouri

Shannon

et al. 2011

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Section: To the Editorsupporting

confidence: 91%

“…We read with great interest the recent article by Radzikowski et al 1 on immunogenicity of the hepatitis A virus (HAV) vaccine in pediatric patients with inflammatory bowel disease (IBD). As outlined by the authors, there are few studies investigating the immune response to vaccinations in children with IBD.…”

Section: To the Editormentioning

confidence: 97%

Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab

Moses

Alkhouri

Shannon

et al. 2011

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

“…Modified dosing regimens, including doubling the standard antigen dose, might increase response rates in immunocompromised patients [75]. Conversely, in a pediatric IBD study of hepatitis A vaccine, the rate of seroconversion after the second dose was 97 %, which did not differ from the rate of 100 % in healthy children [76]. Moreover, several studies have concluded that the influenza vaccine is safe and effective in both children and adults with various chronic diseases [77][78][79][80][81][82][83][84][85].…”

Section: Vaccinationsmentioning

confidence: 82%

Long-Term Safety of Immunomodulators in Pediatric Inflammatory Diseases

2014

View full text Add to dashboard Cite

The medical management of chronic inflammatory disorders in children, including mainly inflammatory bowel diseases and rheumatic diseases, has evolved dramatically over recent years with the advent of disease-modifying drugs such as immunomodulators and biological agents capable of interrupting the inflammatory cascade underlying these disorders. These agents are generally administered in patients who are refractory to conventional therapies. However, there is growing support that their use in the initial phases of these disorders, especially in pediatric patients, could interrupt and cease the inflammatory process. Thus, the aims of therapy have transitioned from symptomatic control to the achievement of deeper remission, including the healing of the inflammatory lesions combined with symptomatic remission. Therefore, more patients are currently receiving immunomodulators or biologics, frequently in addition to corticosteroids. Immunosuppression due to these therapies increases safety concerns, particularly regarding the risk of infections and malignancies. The available literature highlights how the combination of more than one of these therapies, especially if the combination includes corticosteroids, amplifies the risk of severe opportunistic infections. Otherwise, the infections described are mainly mild. Regarding malignancies, the overall risk associated with treatment appears non-significant in pediatric populations, but an appropriate benefit/risk assessment is recommended prior to the introduction of aggressive treatments such as immunomodulants and biologics. The background cancer risk related to the disease itself remains an issue. Protracted follow-up programs are needed, and the results from international multicenter registries are awaited to better understand the true risk related to therapy of these pediatric populations.

show abstract

“…In two studies assessing the immune response to the hepatitis A vaccine, 97-100% of children with IBD achieved seroprotection [25,26]. There was no significant difference in the rate of seroconversion between IBD patients and healthy controls.…”

Section: Vaccine Immunogenicity In Children With Ibdmentioning

confidence: 90%

“…It is important to emphasise that the examined vaccines appeared to be safe in all of the above studies [20][21][22][23][24][25][26][27][28][29]. The most common adverse effects were reactions at the local injection site that manifested as erythema, induration, or tenderness [21][22][23][24][25][26]29].…”

Section: Vaccine Safetymentioning

confidence: 99%